Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193963 | 1.00 | CA12 (0.32) | CA12CA7CA14 | |
| SCHEMBL667155 | 1.00 | CA12 (0.32) | CA12CA7CA14 | |
| SCHEMBL4743 | 0.86 | CA12 (0.40) | CA12CA7CA14 | |
| SCHEMBL3547119 | 0.81 | — | — | |
| SCHEMBL15836240 | 0.73 | CA12 (0.58) | CA12CA7CA14 | |
| SCHEMBL48337 | 0.73 | — | — | |
| SCHEMBL492204 | 0.69 | — | — | |
| SCHEMBL667583 | 0.69 | — | — | |
| SCHEMBL1434773 | 0.69 | — | — | |
| SCHEMBL1679214 | 0.69 | CA12 (0.59) | CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | BET1, PGGT1B, TMPO | CA12 2550/4885CA7 436/4885CA14 2590/4885 |
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | CA12 1901/4885CA7 642/4885CA14 1514/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | CA12 1901/4885CA7 642/4885CA14 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.